Ticker

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2026. Financial Results Revenue The revenues for the second quarter of fiscal 2026 were $7.8 million compared to $7.9 million for the second quarter of fiscal 2025, a…

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company's previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was…

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company's latest FACT…

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL - Get Free Report) shares passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $3.72 and traded as low as $3.41. Cryo-Cell International shares last traded at $3.56, with a volume of 10,098 shares. Cryo-Cell International Stock